Profile: Diana Chow

Diana Chow
Diana Chow, Ph.D.
Professor of Pharmaceutics
Director, Institute of Drug Education and Research
Department of Pharmacological and Pharmaceutical Sciences
532 Texas Medical Center Campus
Houston, TX 77030
832-842-8308
832-842-8305 (fax)
DChow@uh.edu

Education

B.S. in Pharmacy, National Taiwan University, School of Pharmacy
M.S. in Natural Product Chemistry College of Pharmacy, Ohio State University
Ph.D. (Pharmaceutics), University of British Columbia, Canada

Research Interests

  • Liposomal formulation of 9-nitro-camptothecin and derivatives - Formulation and pharmacokinetic and pharmacodynamic evaluations
  • Microemulsion formulation of highly insoluble drugs, using taxol as model compounds
  • Protection of natural and photo-aging, and skin cancer by derivatives of Tempol, and its mechanisms

Patents

Parenteral busulfan for treatment of malignant disease.*

USA patent 5,430,057 (granted July 1995)
USA patent 5,559,148 (granted September 1996)
Australia patent 694141 (granted November 1999)

*Product of Busulfex approved by FDA in 1999 (on market in U.S., Canada, Israel, Europe and Asia since 1999; on market in Australia since 2005)

Parenteral and oral formulations of benzimidazoles.

USA Patent 7,419,996 (granted September 2008)
International and U.S. patent continuations pending

Courses

  • PHAR 5432 Pharmacokinetics
  • PHAR 5672, Clinical Pharmaceutical Research (rotation)
  • PCEU 6341/PCEU 6198, Advanced Pharmacokinetics
  • PCEU 6345/PCEU 6198, Advanced Pharmaceutics II, Drug Delivery

Selected Publications

Journal Articles

Grossman RG, Fehlings M, Frankowski R, Burau KD, Chow D, Tator C, Teng Y, Toups EG, Harrop JS, Aarabi B, Shaffrey C, Johnson MM, Harkema S, Boakye M, Guest J, Wilson JR. A Prospective Multicenter Phase 1 Matched Comparison Group Trial of Safety, Pharmacokinetics, and Preliminary Efficacy of Riluzole in Patients with Traumatic Spinal Cord Injury. J Neurotrauma. 2013 Jul 16 [Epub ahead of print] PMID: 2385943

Wu Y, Satkunendrarajah K, Teng Y, Chow DS, Buttigieg J, Fehlings MG. Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury. J Neurotrauma. 2013 Mar 15;30(6):441-52. doi: 10.1089/neu.2012.2622. Epub 2013 Mar 21. PMID: 23517137

He J, Gao S, Hu M, Chow DS, Tam VH. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother. 2013 May;68(5):1104-10. doi: 10.1093/jac/dks536. Epub 2013 Jan 22. PMID: 2334112

Chow DS, Teng Y, Toups EG, Aarabi B, Harrop JS, Shaffrey CI, Johnson MM, Boakye M, Frankowski RF, Fehlings MG, Grossman RG. Pharmacology of riluzole in acute spinal cord injury. J Neurosurg Spine. 2012 Sep;17(1 Suppl):129-40. doi: 10.3171/2012.5.AOSPINE12112. PMID: 22985379

Dong D, Wu B, Chow D, Hu M. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metab Rev. 2012 May;44(2):192-208. doi: 10.3109/03602532.2011.645580. Epub 2012 Jan 18. Review. PMID: 22251142

Wu Y, Satkundrarajah K, Teng Y, Chow DS, Fehlings MG. Evaluation of the sodium-glutamate blocker riluzole in a preclinical model of ervical spinal cord injury. Evid Based Spine Care J. 2010 Aug;1(2):71-2. doi: 10.1055/s-0030-1267047. PMID: 23637674

He J, Figueroa DA, Lim TP, Chow DS, Tam VH. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 degrees C. Am J Health Syst Pharm. 2010 Jul 15;67(14):1191-4.

J. He, K.R. Ledesma, W-Y. Lam, D. A. Figueroa, T-P. Lim, D. S-L. Chow, V. H. Tam. Variability of polymaxin B major components in commercial formulations. International Journal of Antimicrobial Agents, 2010 Mar;35(3):308-10.

A. Nornoo, D. Osborne and D. S-L. Chow. Cremophor-free intravenous microemulsions for paclitaxel (I): Formulation, cytotoxicity and hemolysis. International Journal of Pharmaceutics [Impact Factor (IF) 2.408], 10.1016/j.ijpharm.2007.07.042; 349: 108-116, 2008.

A. Nornoo and D. S-L. Chow. Cremophor-free intravenous microemulsions for paclitaxel (II):  Stability, in vitro release and pharmacokinetics. International Journal of Pharmaceutics [IF 2.408], 10.1016/j.ijpharm.2007.07.043; 349: 117-123, 2008.

L. Chun, W. Wang, Q. Wu, S. Ke, J. Houston, E. Sevick-Muraca, L. Dong, D. S-L. Chow, C. Charnsangavej and J.G. Gelovani. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nuclear Medicine and Biology [IF 2.478], 33: 349-358, 2006.

I.O. Poon, D. S-L. Chow, and D. Liang. Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products. American Journal of Health-System Pharmacy (AHSP)[IF 1.935], 63: 2128 - 2134, 2006.

X. Wen, Q-P. Wu, S. Ke, S. Wallace, C. Charnsangavej, P. Huang, D. Liang,  D. S-L. Chow and C. Li, Improved radiolabeling of PEGylated protein: Pegylated anexin V for noninvasive imaging of tumor apoptosis. Cancer Biotherapy & Radiopharmaceuticals [IF 1.763], 18:819-827, 2003.

Book Chapters

D. S-L. Chow, L. Gong, M.D. Wolfe and B.C. Giovanella, “Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitrocamptothecin”, The Camptothecins: Unfolding Their Anticancer Potential, Annals of The New York Academy of Sciences [IF 1.731], 922: 164-174, 2000. 
 
D. Hsieh, D. Chow  and J. Chen, “Selective Drug Targeting”, Controlled Released System: Fabrication Technology, Vol. II, CRC Press, pp.145-162 1988.

Meeting Abstracts and Presentations

Fady Ibrahim, Kemi Cui, Pamela New, Lulu Wang, Hong Zhao, Stephen Wong and Diana S-L. Chow, “Dual Efficacy of Lazaroid U-74389G Liposomes in Glioblastoma Mouse Model”. Presented in the 102nd Annual Meeting of AACR, Orlando, FL, April 6, 2011.

Roland Ako, Shi-Ming Tu and Diana S-L. Chow, "Comparative pharmacokinetics of diethylstilbestrol from oral suspension and oral dissolving film (ODF)." Presented in the 102nd Annual Meeting of AACR, Orlando, FL, April 4, 2011.

Tanay Samant and Diana S-L. Chow, "Development of nanosuspension formulation of diethylstilbestrol and effect of particle size on the in vitro drug release." Presented in the 102nd Annual Meeting of American Association for Cancer Research (AACR), Orlando, FL, April 3, 2011.

Fady Ibrahim, Pamela New and Diana S-L. Chow. “Formulation and Pharmacokinetics of Lazaroid U-74389G (LAZ) Liposomes in Rats”. Presented at the 101st Annual Meeting of American Association for Cancer Research (AACR), Washington, D.C., April 17-21, 2010.

Fady Ibrahim, Pamela New and Diana S-L. Chow. “Effects of particle size and charge modification on biodistribution of Lazaroid U74389G from nanosuspensions”. Presented at 23rd Annual Meeting, American Association of Pharmaceutical Scientists (AAPS), Los Angeles, CA, November 8-12, 2009.

Ting Zhu, Jinyang Hong, Jaymin C. Shah and Diana S-L. Chow. “Development and validation of in vitro-in vivo correlation (IVIVC) for sustained-release Cefazolin-loaded PLGA microspheres”. Presented at 23rd Annual Meeting, AAPS, Los Angeles, CA, November 8-12, 2009.

Roland Ako, Fady Ibrahim, Johnny S.W. Lau, Patricia Jensen-Loewe, Shi-Ming Tu  and Diana S-L. Chow. Liquid chromatography tadem mass spectrometry (LC/MS/MS) assay for diethylstilbestrol in plasma samples of recurrent prostate cancer patients”. Presented at 23rd Annual Meeting, AAPS, Los Angeles, CA, November 8-12, 2009.

Yang Teng, Elizabeth G. Toups, Robert G. Grossman and Diana S-L. Chow. “High performance liquid chromatographic assay for Riluzole in human plasma and cerebrospinal fluid (CSF) samples”. Presented at 23rd Annual Meeting, AAPS, Los Angeles, CA, November 8-12, 2009.

Jie He, D.A. Figueroa, Diana S-L. Chow, Vincent H. Tam.  “Stability of polymyxin B (PB) sulfate in saline infusion gags at different storage temperatures”. Presented at 23rd Annual Meeting, AAPS, Los Angeles, CA, November 8-12, 2009.

Fady Ibrahim, Pamela New, Bin S. Teh and Diana S-L. Chow. “Comparative release profiles of Lazaroid U-74389G microspheres in plasma and CSF”. Presented at the 100th Annual Meeting of AACR, Denver, CO, April 18-22, 2009.

Diana S-L. Chow, Roland Ako, Fady Ibrahim, Johnny S.W. Lau, Patricia Jensen-Loewe and Shi-Ming Tu. “Pharmacokinetics and efficacy of oral diethylstilbestrol (DES) in recurrent prostate cancer”. Presented in at 100th Annual Meeting of AACR, Denver, CO, April 18-22, 2009.

Elimika Pfuma, Beppino Giovanella, Jim Sai-Ching Yeung and Diana S-L. Chow. “Combination efficacy of CZ48 and manumycin A in NSCLC H460 bearing Swiss athymic mouse model”. Presented at the 100th Annual Meeting of AACR, Denver, CO, April 18-22, 2009.

Ting Zhu, Jinyang Hong, Jaymin C. Shah and Diana S-L. Chow. “Differential pharmacokinetic performance of cefazolin loaded poly (D,L-lactide-co-glycolide) microspheres of various release kinetics in rat model and their in vitro-in vivo correlations”. Presented at the 22nd Annual Meeting, AAPS, Atlanta, GA, November 11-15, 2008.

Elimika Pfuma, Beppino Giovanella, Jim Sai-Ching Yeung and Diana S-L. Chow. “Pharmacokinetic dose linearity and tumor/plasma exposures of CZ48 in Swiss athymic mouse model”. Presented at the 22nd Annual Meeting, AAPS, Atlanta, GA, November 11-15, 2008.

Ting Zhu, Jinyang Hong, Jaymin C. Shah and Diana S-L. Chow. “Distinct pharmacokinetic performance of biodegradable microspheres of hydrophilic cefazolin with different release characteristics”. Presented at the 35th Annual Meeting and Exposition of the Controlled Release Society (CRS), New York, NY, July 12-16, 2008 

Yulan Qi, Pranav Gupta, Diana S-L. Chow. “Comparative inter-species scaling and prediction of human pharmacokinetic parameters of antineoplastic mebendazole from nanoemulsions of different droplet sizes." Presented at the 99th Annual Meeting of AACR, San Diego, CA., April 12-16, 2008.

Diana S-L. Chow, Pranav Gupta, Peter Wisniecki and Jaymin C. Shah. “Significant impact of drug nanoparticle size on pharmacokinetic disposition of IV antineoplastic mebendazole in rat model”. Presented at the 21st Annual Meeting, AAPS, San Diego, CA, November 11-15, 2007.

Ting Zhu, Jinyang Hong, Jaymin C. Shah and Diana S-L. Chow. “Biodegradable microspheres of hydrophilic cefazolin for sustained release formulations”. Presented at the 21st Annual Meeting, AAPS, San Diego, CA, November 11-15, 2007.

Yulan Qi, Peter Wisniecki, Jaymin C. Shah and Diana S-L. Chow. “Comparative pharmacokinetics and biodistribution of antineoplastic mebendazole from cosolvent and nanosuspension formulations in Swiss nude athymic mice”. Presented at the 21st Annual Meeting, AAPS, San Diego, CA, November 11-15, 2007.

Elimika Pfuma, Beppino Giovanella, Jim Sai-Ching Yeung and Diana S-L. Chow. “Pharmacokinetics of combination treatment of CZ48 with manumycin A in Swiss athymic mouse model”, Presented at the 21st Annual Meeting, AAPS, San Diego, CA, November 11-15, 2007.

Yousif Rojeab, Beppino C. Giovanella and Diana S-L. Chow. “In vitro and in vivo evaluations of microemulsion formulations of CZ48, lactone-stabilized camptothecin-C20-propionate, for transdermal delivery”. Presented at the 34th Annual Meeting and Exposition of the CRS, Long Beach, CA, July 7-11, 2007.

Yulan Qi, Pranav Gupta and Diana S-L. Chow, Comparative pharmacokinetics and biodistributions of mebendazole from cosolvent and nanoemulsion formulations in nude athymic mice. Presented at the 98th Annual Meeting of AACR, Los Angeles, CA., April 16, 2007.

Yousif Rojeab, Beppino C. Giovanella and Diana S-L. Chow. “Comparative pharmacokinetics of microemulsion of CZ48, lactone-stabilized camptothecin-C20-propionate, from different routes of administration in nude mice”. Presented at the 98th Annual Meeting of AACR, Los Angeles, CA., April 16, 2007.

Ting Zhu, Rania Haddadin, Dong Liang and D S-L. Chow, Biodegradable microsphere formulations for CZ48, a lactone-stabilized camptothecin, for potential combination cancer therapy. Presented at the 20th Annual Meeting, AAPS, San Antonio, Texas, November 2, 2006.

Y. Rojeab, B. Giovanella and D S-L. Chow, Topical application of microemulsion of  CZ48, lactone-stabilized camptothecin-C20 propionate, in Swiss-nude mice. Presented at the 20th Annual Meeting, AAPS, San Antonio, Texas, October 30, 2006.

P. Gupta, D. Liang, J. Ma and D.S-L.Chow, Self-emulsifying (SEDDS) and self-microemulsifying drug delivery systems (SMEDDS) for improved oral bioavailability of mebendazole: Effects of particle size and lipid digestion. Presented at the 33rd Annual Meeting and Exposition of the CRS, Vienna, Austria, July 22-26, 2006.

D.S-L.Chow, D.N. Wang, T. Nguyen, D.G. Hwang, B. Stanley, B. Giovanella, S-C. J. Yeung, Scheduling as a factor in combination therapy of a farnesyltransferase inhibitor, manumycin A, with other cell cycle specific chemotherapeutic agents for lung cancer. Presented at the 97th Annual Meeting of AACR, Washington D.C., April 3, 2006.

R. Dababneh, D.S-L.Chow,  S-C. J. Yeung, Sequential versus concurrent treatment of breast cancer cell lines using the farnesyl treansfease inhibitor, manumycin A, and mebendazole. Presented at the 97th Annual Meeting of AACR, Washington D.C., April 3, 2006.

Invited Lectures and Presentations

"Pharmacokinetics and pharmacodynamics of riluzole in patients with acute traumatic spinal cord injury." North American Clinical Trial Network (NACTN) Meeting, Toronto, Ontario, Canada, March 18, 2011.

"Nanoformulations for Cancer Therapy with Significant Impacts on Pharmacokinetics and Pharmacodynamics." University of Toronto, Leslie Dan Faculty of Pharmacy, March 16, 2011.

“Approaches of Nanomedicine Formulations in Cancer Therapy for Achieving Significant Impacts on Pharmacokinetics and Biodistributions.” The 6th Annual Congress of International Drug Discovery Science and Technology (IDDST), Beijing, China, October 18-22, 2008.

“Nanomedicine – self-nanoemulsifying drug delivery system (SNEDDS) and nanosuspension for oral and parenteral formulations in cancer therapy with significant impacts on pharmacokinetics and biodistributions.” Ehrlich II World Conference on Magic Bullets, (for celebrating 100th Anniversary of Nobel Prize to Paul Ehrlich), Nuremberg, Germany, October 3-5, 2008.

“Approaches of self nanoemulsifying drug delivery system (SNEDDS) and nanosuspension for oral and parenteral formulations in cancer therapy with significant impacts onpharmacokinetics and biodistributions.” 2008 Canadian Society of Pharmaceutical Sciences (CSPS) Symposium, Banff, Alberta, Canada, May 22-25, 2008. [unable to attend due to family emergency]

“Pharmacokinetics and pharmacodynamics of riluzole in patients with traumatic spinal cord injury.” North American Clinical Trial Network (NACTN) Meeting, Texas Medical Center, Houston, TX, February 18, 2008.

“Pharmacokinetic considerations in drug discovery and development.” 2006 ACS-Southwestern Regional Meeting, Symposium on Biopharmaceutical Considerations in Designs of New Drugs,” Houston, TX, October 9-22, 2006.

“Novel drug delivery strategies for optimization of cancer therapy- Collaborations with scientists and clinicians at Texas Medical Center.” Silver Anniversary Celebration, College of Pharmacy, University of Houston, at Texas Medical Center, November 11, 2005.

Awards & Honors

  • 2009 Inventor of the Year Award from the Houston Intellectual Property Law Association (HIPLA) in recognition of patented Parenteral Busulfan for Treatment of Malignant Disease

  • Invited Lecturer and Session Co-Chair on Nanotechnologies and Novel Drug Delivery Technologies, The 6th Annual Congress of International Drug Discovery Science and Technology (IDDST), October 18-22, 2008, Beijing, China.

  • Invited Lecturer, Ehrlich II World Conference on Magic Bullets, (for celebrating 100th Anniversary of Nobel Prize to Paul Ehrlich, October 3, 2008, Nuremberg, Germany.

  • Plenary Lecturer, Canadian Society of Pharmaceutical Sciences (CSPS) Symposium 2008, May 23, 2008. Banff, Alberta, Canada.

  • Invited Lecturer, North American Clinical Trial Network (NACTN) Meeting, February 18, 2008, Texas Medical Center, Houston, TX.

  • Faculty Service Excellence Award, College of Pharmacy, University of Houston, May 2007.

  • 2006 Faculty Scholar Award in Cancer Research, American Association for Cancer Research – Minority-Serving Institution (AACR-MSI), Washington D.C., April 2006.

  • 2005 Faculty Scholar Award in Cancer Research, American Association for Cancer Research – Minority-Serving Institution (AACR-MSI), Anaheim, California, April 2005

  • Invited Lecturer, Ehrlich I World Conference (for celebrating Nobel Laureate Paul Ehrlich’s 150th Birthday), September 9, 2004, Nuremberg, Germany. [Only 1,000 scientists and clinicians were invited from 84 countries.]

  • Gillson Longenbaugh Foundation Research Award, 2003-2008.

  • Plenary Lecturer, Conference on The Camptothecins: Unfolding Their Anticancer Potential, March 18, 2000, Ritz-Carlton Pentagon City, Arlington, Virginia.

Affiliations

  • Member, New York Academy of Sciences, 2000-Present
  • Member, American Association for Cancer Research, 1995-Present
  • Member, American Association of Pharmaceutical Scientists, 1985-Present
  • Member, Controlled Release Society, 1982-Present
  • Member, Society for In-Vitro Biology (Tissue Culture Association, 1981-1994), 1981-Present
  • Member, American Pharmaceutical Association, 1978-Present
  • Member, American Association of College of Pharmacy, 1982-Present
  • Member, Pharmacy Examining Board of Canada (P.E.B.C. Registrant of Pharmacists), 1979-Present